ESMO Calls for Cancer Care Integration in EU Global Health Resilience Initiative (GHRI) By Ogkologos - March 24, 2026 176 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC MOST POPULAR BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... May 19, 2021 Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... November 15, 2024 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 Introducing our new podcast for researchers February 4, 2022 Load more HOT NEWS Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... When Prenatal DNA Tests Point to Cancer Early-onset cancer: why are more young adults being diagnosed? Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer
